Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. (Q64940048)
Jump to navigation
Jump to search
scientific article published on 27 August 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. |
scientific article published on 27 August 2018 |
Statements
Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. (English)
1 reference
Ying Wang
1 reference
Lijing Su
1 reference
Matthew D Morin
1 reference
Brian T Jones
1 reference
Yuto Mifune
1 reference
Hexin Shi
1 reference
Kuan-Wen Wang
1 reference
Xiaoming Zhan
1 reference
Aijie Liu
1 reference
Jianhui Wang
1 reference
Xiaohong Li
1 reference
Miao Tang
1 reference
Sara Ludwig
1 reference
Kejin Zhou
1 reference
Daniel J Siegwart
1 reference
Eva Marie Y Moresco
1 reference
Hong Zhang
1 reference
Dale L Boger
1 reference
Bruce Beutler
1 reference
27 August 2018
1 reference
115
1 reference
37
1 reference
E8698-E8706
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference